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Background: Adiponectin plays a role as a positive contributor to the stabilization of atherosclerotic plaques.
Circulating total adiponectin (Total-APN) levels associates with the number of coronary vessels in men with
coronary artery disease (CAD). We recently reported that adiponectin binds to C1q in human blood, and serum
C1q-binding adiponectin (C1q-APN) /Total-APN levels are associated with CAD in type 2 diabetic subjects. The
present study investigated the relationship between circulating C1q-APN levels and the number of angiographic
coronary artery vessel in male subjects.
Methods: The study subjects were 53 male Japanese patients who underwent diagnostic coronary angiography.
Blood total adiponectin (Total-APN), high-molecular weight adiponectin (HMW-APN), C1q-APN and C1q were measured
by enzyme-linked immunosorbent assays.
Results: Serum C1q-APN/Total-APN ratio significantly increased in subjects with single and multi-vessel coronary diseases
(p = 0.029 for trend, the Kruskal-Wallis test). However, serum Total-APN, HMW-APN, C1q-APN and C1q levels did not
correlate with number of diseased coronary vessels.
Conclusion: Serum C1q-APN/Total-APN ratio progressively increases in men with single and multi-vessel coronary
disease.
Trial registration: UMIN000002997
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Vulnerable atheromatous plaques lead to coronary plaque
disruption with superimposed thrombosis [1], which is
often manifested as angiographically complex lesions [2].
Adiponectin, an adipocyte-derived blood protein [3] is
present abundantly in injured arteries [4,5] and also
suppresses macrophage foam cell transformation [6,7]
and increases the expression of tissue inhibitor of
metalloproteinase-1 in monocyte-derived macrophages
through induction of interleukin-10 [8], suggesting that
adiponectin may be a positive contributor to the stabilization
of atherosclerotic plaques. Previous studies reported* Correspondence: kkishida@imed2.med.osaka-u.ac.jp
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levels were associated with coronary lesion complexity
and the numbers of coronary vessels in subjects with
coronary artery disease (CAD) [9-12]. Yu et al. reported
that Total-APN levels decreased progressively as the
number of diseased coronary arteries increased, although
the differences in Total-APN levels among each coronary
lesion severity were not statistically significant [10].
We reported recently that adiponectin bound with C1q
in human blood, and also developed a system to measure
human serum C1q-binding adiponectin (C1q-APN) [13].
Serum C1q-APN/Total-APN ratio correlated with the
metabolic syndrome in male subjects [13], and with
polyvascular diseases and stable CAD in type 2 diabetics
[14,15]. However, the relationship between serum
C1q-APN levels and the number of diseased coronary
arteries remains to be elucidated. The hypothesis tested inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the presence of multi-vessel coronary disease. The main
investigation and results in this study were not in the




The study (#UMIN 000002997) subjects were consecutive
53 male Japanese admitted-patients who underwent
diagnostic coronary angiography for suspected CAD
following chest pain and/or ischemic changes on the
electrocardiogram, and also underwent measurement
of fat distribution by computed tomography scan for
measurement of adipose tissues that was classified to
visceral and subcutaneous fat tissue compartment at
Kenporen Osaka Central Hospital and Department of
Metabolic Medicine, Osaka University Hospital between
April and September 2009. Patients treated with pio-
glitazone, which is known to increase serum levels of
Total-APN [16] and C1q-APN [17], and those with
renal dysfunction (creatinine >1.5 mg/dL) [18] were
excluded from the study. The Medical Ethics Committees
of Osaka University and Kenporen Osaka Central Hospital
approved the protocol of the study. All participants were
Japanese and each gave a written informed consent.
Angiographic morphology of coronary stenosis
Coronary stenosis was assessed morphologically according
to the American College of Cardiology/American Heart
Association (ACC/AHA) [19], and patients were classified
into three groups, as follows: Non-CAD group (control),
patients with no stenosis; Single-vessel group, patients
with > 75% stenosis of one vessel; Multi-vessels group,
patients with > 75% stenosis of two or more vessels.
Angiographic evaluations were performed independently by
2 cardiologists who were blinded to the clinical features of
the patients and, in case of disagreement, the decision was
based on the judgment of a third, more experienced
observer. The interobserver reproducibility for morphologic
assessment of coronary lesions was 90%.
Anthropometry and laboratory tests
Anthropometric variables [height and weight] were
measured in the standing position and body mass
index (BMI) was calculated [=weight (kg)/height (m)2].
Visceral fat area (VFA) and subcutaneous fat area (SFA)
were measured manually on computed tomography scan
at the umbilical level according to our laboratory methods
[20]. Systolic and diastolic blood pressures were measured
with a standard mercury sphygmomanometer on the
left or right arm in the supine position after at least
10-minute rest.Venous blood samples were collected in the morning
after overnight fast for measurement of serum creatinine,
lipids, glucose, and HbA1c (Japan Diabetes Society [JDS]).
The value of HbA1c (%) was estimated as the National
Glycohemoglobin Standardization Program (NGSP)
equivalent value (%), calculated by the formula HbA1c
(%) = HbA1c (JDS,%) + 0.4%. For the purpose of the
present study, serum samples that were obtained at
baseline from each participant were stored promptly
at –20°C. After thawing the samples, serum levels of
Total-APN and high-molecular weight-adiponectin
(HMW-APN) were measured by enzyme-linked immuno-
sorbent assay (ELISA) kits (Human adiponectin ELISA
kit, Human HMW-adiponectin ELISA kit, Otsuka
Pharmaceutical Co. Tokushima, Japan) [3,21]. Serum
levels of C1q-APN (units (U) /mL) and C1q (μg/mL) were
measured by our in-house ELISA, as reported previously
by our group [13]. The intra- and inter-coefficients of
variation (CV) for C1q-APN ELISA are below 4.6%
and 6.7%, respectively. The intra- and inter-CV for C1q
ELISA are below 4.6% and 5.0%, respectively.
Hypertension was defined as systolic blood pres-
sure ≥140mmHg, and/or diastolic blood pressure ≥90mmHg,
or current treatment for hypertension. Diabetes mellitus
was defined according to the World Health Organization
criteria [22], and/or current treatment for diabetes melli-
tus. Dyslipidemia was defined as low-density lipoprotein-
cholesterol concentration of ≥140 mg/dL, triglyceride
concentration ≥150 mg/dL, high-density lipoprotein-
cholesterol concentration <40 mg/dL, and/or treatment
for dyslipidemia.
Statistical analysis
Data are presented as mean ± SEM. Differences in fre-
quencies were examined by the χ2 test. Differences
among groups were compared by one- or two-way
analysis of variance (ANOVA) with Fisher's protected
least significant difference test for multiple-group analysis.
Differences in each adiponectin parameter in numbers of
vessels were analyzed by the Kruskal-Wallis test. In all
cases, p values <0.05 were considered statistically signifi-
cant. All analyses were performed with the JMP Statistical
Discovery Software 9.0 (SAS Institute, Cary, NC).
Results
Single and multiple vessel disease was identified in 72%
(none/single/double/triple = 15/22/13/3). Table 1 summa-
rizes the characteristics of the participating subjects,
according to the number of diseased coronary vessels;
Non-CAD group, Single-vessel group, Multiple-vessels
group. There were no significant differences of age,
BMI, VFA and creatinine among three groups. Serum
Total-APN levels were significantly lower in single-vessel
and multi-vessels groups than in Non-CAD group









p value (Non-CAD group
versus Multi-vessels group)
p value (Single-vessel group
versus Multi-vessels group)
Number 15 22 16
Age, years 65 ± 2 65 ± 2 0.910 66 ± 2 0.889 0.817
Body mass index, kg/m2 25.0 ± 0.9 23.8 ± 0.7 0.666 25.6 ± 1.0 0.359 0.135
Visceral fat area, cm2 111 ± 14 121 ± 14 0.205 123 ± 14 0.255 0.898
Subcutaneous fat area, cm2 137 ± 18 138 ± 12 0.341 141 ± 11 0.394 0.918
Smoking (none-/ex-/current-smoker), n 8/5/2 9/5/8 0.566 3/4/9 0.149 0.230




Hypertension, n 13 16 0.436 11 0.392 0.886
Calcium channel antagonists/angiotensin receptor
blockers/β-blockers/diuretics, n 8/2/2/0 13/12/4/2 6/8/6/2
Dyslipidemia, n 7 14 0.430 10 0.525 0.965
Statins/fibrates/ezetimibe/cholestimide, n 5/1/0/0 10/0/1/1 9/1/0/0
Anti-platelet drugs (aspirin/ticlopidine/clopidogrel), n 4/0/2 22/0/22 16/6/10
Family history of CAD, n 2 2 0.753 5 0.392 0.116
Systolic blood pressure, mmHg 134 ± 4 137 ± 4 0.808 139 ± 5 0.981 0.802
Diastolic blood pressure, mmHg 78 ± 2 74 ± 2 0.135 77 ± 3 0.586 0.407
Hemoglobin A1c (NGSP),% 6.9 ± 0.5 6.4 ± 0.2 0.255 6.6 ± 0.4 0.661 0.519
LDL-C, mg/dL 123 ± 6 110 ± 7 0.193 113 ± 9 0.789 0.132
Triglyceride, mg/dL 124 ± 16 152 ± 19 0.290 125 ± 12 0.969 0.273
HDL-C, mg/dL 61 ± 4 57 ± 4 0.352 48 ± 3 0.005* 0.139
Creatinine, mg/dL 0.82 ± 0.04 0.87 ± 0.06 0.880 0.82 ± 0.02 0.475 0.510
Target lesions (LMCA/LAD/LCX/RCA), n - 0/20/1/1 1/40/13/2
ACC/AHA (Type A/B/C) - 6/12/4 5/7/4
Procedures (PCI/CABG), n - 22/0 15/1
Data are mean ± SEM, or number of subjects analyzed. Differences among groups were compared by one- or two-way analysis of variance (ANOVA) with Fisher's protected least significant difference test for multiple-
group analysis. Differences in frequencies were examined by the χ2 test. CAD, coronary artery disease; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; LMCA, left main coronary



























































































Figure 1 Circulating levels of Total-APN (A), HMW-APN (B),
C1q-APN (C), and C1q (D) in the study population according to
the number of coronary vessels. Differences in each adiponectin
parameter and C1q in numbers of vessel were analyzed by the
Kruskal-Wallis test. Differences among groups were compared by
one- or two-way analysis of variance (ANOVA) with Fisher’s protected
least significant difference test for multiple-group analysis. *p < 0.05,
compared with the Non-CAD group (number of coronary vessel = 0).
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serum C1q-APN and C1q levels among three groups
(Figure 1B-D).
Our groups reported that serum C1q-APN/Total-APN
ratio correlated with polyvascular diseases and stable
CAD in type 2 diabetics [14,15]. It is important to con-
sider not only the absolute amount of adiponectin but
also the levels of relative adiponectin forms in blood.
Serum C1q-APN/Total-APN levels were significantly
higher in single-vessel and multi-vessels groups than
in Non-CAD group (*p < 0.05, Figure 2B). Serum
C1q-APN/Total-APN ratio increased significantly in
men with single and multi-vessel coronary diseases
(#p < 0.05, the Kruskal-Wallis test, Figure 2B). However,
serum HMW-APN/Total-APN, C1q-APN/C1q and Total-
APN/C1q levels did not correlate with the number of
coronary vessels (Figure 2A, C and D).
Discussion
The present study represents the first report demon-
strating that serum C1q-APN/Total-APN ratio increased
progressively in men with single and multi-vessel coronary
disease.
The present study demonstrated that serum Total-
APN levels were significantly lower in single-vessel and
multi-vessels groups than in Non-CAD group (Figure 1A),
as reported previously [10,12], but did not decrease
significantly with the increased numbers of atherosclerotic
coronary vessels (p = 0.132 for trend, Figure 1A). Serum
HMW-APN levels were also significantly lower in multi-
vessels groups than in Non-CAD group (Figure 1B), and
trended to decrease with the increased numbers of athero-
sclerotic coronary vessels (p = 0.074 for trend, Figure 1B).
There was a strong positive relation of between serum
Total-APN and HMW-APN levels in the present study
(p < 0.0001, r = 0.93, data not shown), as reported previously
[21,23]. There are no different characteristics of between
Total-APN and HMW-APN. Interestingly, serum
C1q-APN/Total-APN levels were not only significantly
higher in single-vessel and multi-vessels groups than in
Non-CAD group, but also they increased significantly with
increased numbers of coronary vessels (Figure 2B). We
speculate that adiponectin may be trapped by C1q, as
adiponectin is trapped by cystatin C in renal failure
[24], thereby leading to an inactive adiponectin form,
C1q-APN. However, to date, the precise values for serum
C1q-APN cannot be measured, because the proportion of
blood adiponectin that forms protein complex with C1q
remains unclear. If feasible, we may clarify whether
C1q-APN is an inactive form of adiponectin.
Angiographic assessment of the morphology of coronary
stenosis is well established and considered to be clinically
useful for risk stratification of CAD patients [25,26]. Our
results may indicate that high serum C1q-APN/Total-APNcould perhaps be used to predict the occurrence of future
cardiovascular events; however, further prospective studies











































































Numbers of angiographic 
atherosclerotic coronary vessels
Figure 2 Circulating levels of HMW-APN/Total-APN (A),
C1q-APN/Total-APN (B), C1q-APN/C1q (C), and Total-APN/C1q
(D) in the study population according to the number of coronary
vessels. Differences in each adiponectin parameter in numbers of
vessel were analyzed by the Kruskal-Wallis test (# p < 0.05). Differences
among groups were compared by one- or two-way analysis of variance
(ANOVA) with Fisher's protected least significant difference test for
multiple-group analysis. *p < 0.05, compared with the Non-CAD group
(number of coronary vessel = 0).
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did not investigate angiographic severity scores such as
Jeopardy score, Gensini score or SYNTAX score, and
coronary lesions using intravascular ultrasound. Therefore,
further studies including vulnerability using intravascular
ultrasound are required in the future.Conclusion
The present study indicates that serum C1q-APN/Total-
APN ratio increased progressively in men with single
and multi-vessel coronary disease. This study suggested
serum C1q-APN/Total-APN might be a useful biomarker
of coronary lesions in patients with CAD. Routine
measurement of adiponectin in patients with lifestyle-
related diseases is highly recommended [23]. Measurements
of serum Total-APN plus C1q-APN may become instru-
mental to predict numbers of angiographic atherosclerotic
coronary vessels.Study limitations
The present study has several limitations. First, all patients
in this study were Japanese men and any differences from
other ethnic groups are unknown. It is well-known that
there is difference of circulating adiponectin levels in
between males and females [27]. Further studies for
females are required in the future. Second, the number of
patients was relatively small. Based upon 80% power
to detect statistically significant differences (p = 0.05;
two-sided) as our group reported previously [13,14,28], a
sample size of at least 15 patients in each group was
required to demonstrate (total sample size = 45). Further a
larger scale study is required in the future. Third, among
patients with normal coronaries, coronary spastic patients
with non-significant organic stenosis could not be excluded
from the study, because they did not undergo intracoronary
injection of acetylcholine chloride. There might be a patient
selection bias. Fourth, this is a cross-sectional study,
making it difficult to establish a cause-effect relationship.
Further prospective studies should be conducted to analyze
this relationship. Finally, the current study did not include
the effects of data of each adiponectin parameter, such as
pharmacological agents.
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